Millennium Management
ELVN icon

Millennium Management’s Enliven Therapeutics ELVN Stock Holding History

Millennium Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
345,318
+48,371
+16% +$1.34M 0.01% 1883
2025
Q4 		$4.57M Sell
296,947
-84,458
-22% -$1.68M ﹤0.01% 3110
2025
Q3 		$7.81M Buy
381,405
+62,956
+20% +$1.27M ﹤0.01% 2642
2025
Q2 		$6.39M Buy
318,449
+185,562
+140% +$3.51M ﹤0.01% 2733
2025
Q1 		$2.62M Buy
132,887
+82,083
+162% +$1.77M ﹤0.01% 3518
2024
Q4 		$1.14M Buy
50,804
+26,449
+109% +$686K ﹤0.01% 4089
2024
Q3 		$622K Buy
+24,355
New +$564K ﹤0.01% 4660
2023
Q2 		– Sell
-46,874
Closed -$1.03M – 6228
2023
Q1 		$1.03M Buy
+46,874
New +$953K ﹤0.01% 4073
2022
Q2 		– Sell
-2,577
Closed -$19K – 7088
2022
Q1 		$19K Sell
2,577
-15,386
-86% -$101K ﹤0.01% 6646
2021
Q4 		$162K Sell
17,963
-7,988
-31% -$105K ﹤0.01% 6038
2021
Q3 		$424K Buy
25,951
+17,235
+198% +$358K ﹤0.01% 5498
2021
Q2 		$275K Buy
8,716
+4,321
+98% +$134K ﹤0.01% 5798
2021
Q1 		$148K Buy
4,395
+4
+0.1% +$203 ﹤0.01% 5593
2020
Q4 		$387K Buy
+4,391
New +$369K ﹤0.01% 4395
2020
Q3 		– Sell
-2,768
Closed -$306K – 4538
2020
Q2 		$306K Buy
+2,768
New +$310K ﹤0.01% 3652

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's ELVN Position: Q1 2026 in Review

Millennium Management increased its Enliven Therapeutics (ELVN) stake by 16% in Q1 2026, buying an estimated $1.34M and bringing the position to 345,318 shares worth $13.5M. The position accounts for 0.01% of the portfolio, ranked #1883.

Millennium Management first reported a position in ELVN in Q2 2020 and has held it in 15 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Millennium Management held 345,318 shares of Enliven Therapeutics worth $13.5M as of Q1 2026.
  • Millennium Management bought 48,371 Enliven Therapeutics shares in Q1 2026, an estimated $1.34M.
  • Enliven Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1883 holding.
  • Millennium Management first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.